Descripción de la empresa
Cellectis S.A. operates as a clinical stage biotechnological enterprise dedicated to developing products founded on gene-editing technologies, specifically maintaining a portfolio of allogeneic chimeric antigen receptor T-cells for immuno-oncology alongside gene therapy candidates for various therapeutic indications. The company functions within the Healthcare sector and the Biotechnology industry, positions that signify a focus on high-risk, high-reward research and development activities aimed at creating novel medical treatments rather than traditional manufacturing or service delivery. Cellectis S.A. currently possesses a market capitalization of $337.99M, generates annual revenue of $79.59M, and employs a workforce of 224 individuals to execute its strategic initiatives. These valuation and revenue figures indicate that the company occupies a mid-cap position within the biotechnology landscape, suggesting it is an established entity that has moved beyond the earliest startup phase but has not yet achieved the massive scale of fully commercialized pharmaceutical giants, thereby positioning it in a critical stage of transitioning from clinical trials toward potential commercial viability.
Salud financiera
The financial performance of Cellectis S.A. is characterized by a revenue of $79.59M for the trailing twelve months, a net income of $-67,593,000, and an EBITDA of $-21,750,000, revealing a significant gap between top-line generation and bottom-line profitability that highlights a cost structure dominated by heavy research and development expenditures. The company reports a free cash flow of $-25,282,376, which indicates a consumption of cash reserves to fund ongoing operations and development programs, thereby limiting immediate financial flexibility until future revenue streams expand or cost efficiency improves. Margin analysis shows a gross margin of 100.0%, reflecting the nature of the biotechnology sector where revenue is often booked upon licensing or milestone payments without direct manufacturing costs at this stage, while an operating margin of -142.1% and a profit margin of -84.9% demonstrate substantial operational losses relative to revenue, signaling that the company is not yet profitable at the operational or net levels. Regarding capital structure, the firm holds $206.38M in cash against $86.69M in debt, resulting in a debt-to-equity ratio of 114.22, which suggests a highly leveraged balance sheet relative to equity but one supported by a substantial cash buffer that provides a runway for operations. The current ratio stands at 1.62, indicating that the company possesses 1.62 dollars of current assets for every dollar of current liabilities, which points to adequate short-term liquidity to meet its immediate obligations without immediate distress. Return metrics display a return on equity of -65.3% and a return on assets of -5.8%, figures that reveal that management effectiveness in generating returns on the capital base is currently negative, a common characteristic for clinical-stage companies investing heavily in future growth rather than returning value to shareholders through earnings.
Evaluación de valoración
Valuation metrics for Cellectis S.A. include a P/E Ratio (TTM) of N/A due to negative earnings and a Forward P/E of -5.42, the divergence between these figures implies that the market is pricing in a future trajectory where earnings may turn positive, though the current forward metric remains negative due to anticipated continued losses in the short term. The price-to-book ratio is recorded at 3.20, indicating that the market values the company at more than three times its book value, which suggests a significant premium assigned to the intangible assets, such as intellectual property and clinical data, that are not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 4.25 and an EV/EBITDA of -5.71, which suggest that investors are willing to pay a multiple of over four times revenue for the company despite its lack of profitability, reflecting high expectations regarding the potential value of its gene-editing pipeline. Price action over the last year has seen the stock fluctuate between a 52-Week High of $5.48 and a 52-Week Low of $1.17, meaning the current trading price sits dynamically within this range, reflecting the high volatility typical of biotechnology equities awaiting clinical data readouts. The beta value is 2.71, which signifies that the stock price is expected to be nearly three times as volatile as the broader market, amplifying both potential gains and losses during periods of market turbulence.
Growth & Income
Cellectis S.A. exhibits a revenue growth rate of -19.5% year over year, while earnings growth is N/A due to negative earnings, indicating that the company is currently in a contractionary phase regarding revenue and has no positive earnings trajectory to compare against. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which explains that the firm reinvests all available resources and any generated cash flow back into research, development, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile for Cellectis S.A. is defined by a lack of current profitability and negative revenue growth, yet it maintains a cash-rich position that allows it to continue its aggressive development strategy in the gene-editing space without the immediate pressure of generating cash flow for external stakeholders.